Figure 1. IFN-I signaling in cancer regulates its immunogenicity.
“Hot” immunogenic tumors could be better recognized by the immune system than “cold” tumors. IFN-I-derived from cancer cells could launch a large interferon-stimulated genes (ISG) transcriptional program and promote effector immune cell trafficking to the tumor bed. In addition, IFN-I could also promote APC cross-priming of T-cells.